Resistance mechanisms to anti-PD cancer immunotherapy
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
Designing neoantigen cancer vaccines, trials, and outcomes
Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed
in cancer cells. These highly immunogenic antigens may trigger the immune system to …
in cancer cells. These highly immunogenic antigens may trigger the immune system to …
Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label …
DM O'Malley, M Neffa, BJ Monk, T Melkadze… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-
lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising …
lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising …
Current progresses and challenges of immunotherapy in triple-negative breast cancer
K Mediratta, S El-Sahli, V D'Costa, L Wang - Cancers, 2020 - mdpi.com
Simple Summary The breakthrough of immunotherapy in melanoma has generated a
glimmer of hope for lethal triple negative breast cancer (TNBC). This review summarizes the …
glimmer of hope for lethal triple negative breast cancer (TNBC). This review summarizes the …
Current and emerging therapies for neuroendocrine prostate cancer
Neuroendocrine prostate cancer is a histological variant of prostate cancer that is
characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine …
characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine …
Immune checkpoint inhibitors in colorectal cancer: challenges and future prospects
S Makaremi, Z Asadzadeh, N Hemmat… - Biomedicines, 2021 - mdpi.com
Immunotherapy is a new pillar of cancer therapy that provides novel opportunities to treat
solid tumors. In this context, the development of new drugs targeting immune checkpoints is …
solid tumors. In this context, the development of new drugs targeting immune checkpoints is …
Endocrine side effects of immune checkpoint inhibitors
Z Cardona, JA Sosman, S Chandra… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for
numerous malignancies. However, due to their association with autoimmunity, ICIs have …
numerous malignancies. However, due to their association with autoimmunity, ICIs have …
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
J Kang, C Zhang, WZ Zhong - Cancer Communications, 2021 - Wiley Online Library
Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
Y Zhao, Y Ma, A Zang, Y Cheng, Y Zhang… - Journal of Hematology & …, 2023 - Springer
Abstract Background QL1706 (PSB205) is a single bifunctional MabPair (a novel technical
platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and …
platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and …
Development of anticancer peptides using artificial intelligence and combinational therapy for cancer therapeutics
Cancer is a group of diseases causing abnormal cell growth, altering the genome, and
invading or spreading to other parts of the body. Among therapeutic peptide drugs …
invading or spreading to other parts of the body. Among therapeutic peptide drugs …